MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Orthofix Medical Net Income 2011-2026 | OFIX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Orthofix Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -92.2 M | -126 M | -151 M | -19.7 M | -38.4 M | 2.52 M | -28.5 M | 13.8 M | 6.22 M | 3.06 M | -2.81 M | -8.54 M | -25.5 M | 51.3 M | -1.07 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 51.3 M | -151 M | -27.8 M |
Quarterly Net Income Orthofix Medical
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20.9 M | - | -22.8 M | -14.1 M | -53.1 M | - | -27.4 M | -33.4 M | -36 M | - | -28.9 M | -39.4 M | -60.9 M | - | -10.7 M | 2.49 M | -4.46 M | - | -2.17 M | 2.42 M | -5.82 M | - | 4.65 M | -18.4 M | 25.7 M | 11.7 M | -40.5 M | -547 K | 897 K | 8.87 M | -1.21 M | 925 K | 5.23 M | 1.57 M | 3.46 M | 3.85 M | -2.65 M | -3.24 M | 9.9 M | -7.44 M | 3.84 M | 3.37 M | -1.37 M | 3.57 M | -8.38 M | -5.8 M | 452 K | -683 K | -2.51 M | -10.4 M | -18.8 M | -3.01 M | 3.45 M | 23 M | 3.75 M | 8.8 M | 7.35 M | 7.89 M | 10.1 M | 5.4 M | -41.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25.7 M | -60.9 M | -6.62 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 11.64 | -8.85 % | $ 330 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | $ 4.17 | 0.97 % | $ 156 M |  France |
 |
Apyx Medical Corporation
APYX
|
-11.2 M | $ 4.05 | -7.11 % | $ 166 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-6.09 M | - | - | $ 3.31 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
-143 M | $ 7.66 | 1.19 % | $ 1.15 B | USA |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
Helius Medical Technologies
HSDT
|
-8.85 M | $ 2.3 | -3.77 % | $ 1.4 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 17.72 | -1.01 % | $ 416 M | USA |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
LENSAR
LNSR
|
-34.3 M | $ 5.54 | -4.97 % | $ 66.2 M | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
Pulmonx Corporation
LUNG
|
-54 M | $ 1.27 | -5.22 % | $ 51.7 M | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.5 | -8.16 % | $ 31.1 M | USA |
 |
LivaNova PLC
LIVN
|
-242 M | $ 70.0 | -2.33 % | $ 3.82 B |  Britain |
 |
MiMedx Group
MDXG
|
48.6 M | $ 3.56 | 0.28 % | $ 526 M | USA |
 |
Delcath Systems
DCTH
|
2.7 M | $ 11.07 | -3.4 % | $ 397 M | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
-4.44 M | $ 1.01 | - | $ 17.1 M | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |
 |
Myomo
MYO
|
-15.6 M | $ 0.91 | 2.49 % | $ 38.1 M | USA |
 |
Electromed
ELMD
|
7.54 M | $ 35.68 | -2.25 % | $ 302 M | USA |
 |
Butterfly Network
BFLY
|
-77.1 M | $ 3.83 | -6.59 % | $ 811 M | USA |
 |
Insulet Corporation
PODD
|
247 M | $ 147.46 | -0.82 % | $ 10.4 B | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
Second Sight Medical Products
EYES
|
26.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 2.27 | -5.62 % | $ 6.3 M | USA |
 |
Globus Medical
GMED
|
538 M | $ 76.64 | -0.74 % | $ 10.4 B | USA |
 |
Profound Medical Corp.
PROF
|
-42.6 M | $ 6.97 | -3.19 % | $ 211 M | Canada |
 |
Stryker Corporation
SYK
|
849 M | $ 306.76 | 0.41 % | $ 117 B | USA |
 |
CONMED Corporation
CNMD
|
47.1 M | $ 35.49 | -2.34 % | $ 1.1 B | USA |
 |
Tactile Systems Technology
TCMD
|
19.1 M | $ 22.74 | -1.3 % | $ 520 M | USA |
 |
Inspire Medical Systems
INSP
|
145 M | $ 40.05 | -6.12 % | $ 1.18 B | USA |
 |
Tandem Diabetes Care
TNDM
|
-205 M | $ 12.82 | -9.4 % | $ 872 M | USA |